Table 2 Overview of studies for dyslipidemia included in the final analysis (N = 11)
Search type | Study: first author; publication date | Brief study design | Sample size (N); characteristics | Prevalence | Awareness | Screening | Diagnosis | Treatment | Adherence | Control | Remarks |
|---|---|---|---|---|---|---|---|---|---|---|---|
Data as per the MAPS inclusion criteria | |||||||||||
Unstructured | Ministry of Health & population, Egypt Preventive Sector Central Epidemiology and Disease Surveillance (ESU) Non-Communicable Disease Surveillance Unit (NCDSU); 2006 | National cross-sectional survey | N = 9780; participants (15–65 years) | 19.4% | x | x | x | x | x | x | NA |
WHO and ARE-Ministry of Health & Population: Egypt National STEPwise Survey of Non-Communicable Diseases Risk Factors 2011-2012; 2012 | Multistage cluster sample design | N = 5300; participants (15–65 years) | 36.8% | x | x | x | x | x | x | NA | |
Supplementary Record | Egypt National STEPwise Survey For Noncommunicable Diseases Risk Factors Report; 2017 | National cross-sectional community-based household survey | N = 6680; nationally representative sample of Egyptian adults (15–69 years). | 19.2% | x | 8.6% | x | x | x | x | NA |
Data deviates from the MAPS inclusion criteria (definitions/special patient subgroups) | |||||||||||
Structured | The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment: El Etriby A; 2013 | Cross-sectional, observational, multinational study | N = 1458; patients (≥ 45 years) on stable statin treatment. | x | x | x | x | x | x | 33.7% | Control data extracted based on target LDL-C attainment |
Lipid profile in Egyptian patients with coronary artery disease: Ibrahim MM; 2013 | Retrospective consecutive sampling of patients with CAD | N = 1000; patients ranged from 19 to 90 years. | 58.7% | x | x | x | x | x | x | Data extracted from patients with stable CAD or had a history MI | |
Centralized Pan-Middle East Survey on the Under- Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt: Reda A; 2014 | Multicenter, observational study | N = 1043; subjects (≥ 18 years) were receiving lipid-lowering drug treatment. | x | 76.0% | x | x | x | x | 32.5% | Control data extracted based on target LDL-C attainment | |
Comparative study between elderly and younger patients with acute coronary syndrome: Obaya M; 2015 | Comparative study between elderly and younger patients with ACS | N = 570; patients were divided into 2 groups: elderly ≥ 60 years; younger < 60 years. | 50.9 | x | x | x | x | x | x | Data extracted from younger patients (< 60 year) presenting with ACS; dyslipidemia not defined | |
Centralized Pan-Middle East Survey on the Under- Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt: Reda A; 2017 | Observational, multicenter, cross-sectional survey | N = 896; Subjects (≥ 18 years) receiving lipid-lowering drug treatment. | x | 75.0% | x | x | x | 59.0% | 34.4% | Data extracted based on LDL-C levels | |
Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome: Sobhy M; 2018 | Prospective, observational study of patients presenting with ACS | N = 199; patients (≥ 18 years) who were hospitalized for ACS and receiving lipid-lowering treatment. | x | x | x | x | 73.9% | x | 5.1% (very high risk; < 70 mg/dL) 27.3% (high risk; < 100 mg/dL) 32. 3% (moderate risk; < 115 mg/dL) 14.3% (low risk; < 130 mg/dL) | Data extracted on investigating selected subpopulations (ACS patients); control data extracted based on target LDL-C attainment corresponding to different risk categories | |
The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross-sectional CardioRisk project: Reda A; 2019 | Multi-center, observational, cross-sectional study of patients presenting with ACS | N = 1681; participants (≥18 years) having a history of lipid-lowering therapy or LDL-C > 70 mg/dL (> 1.81 mmol/L). | 52.50% | x | x | x | x | x | x | Data extracted on investigating ACS patients; dyslipidemia definition is based on LDL-C levels | |
Registry of the Egyptian specialized hypertension clinics: patient risk profiles and geographical differences: El Faramawy A; 2019 | Nationwide Specialized Hypertension Clinics Registry | N = 4701; dyslipidemia considered when LDL ≥ 130 mg/dL, HDL ≤ 50 mg/dL in women and ≤ 40 mg/dL in men, and TG ≥150 mg/dL or if the patient was receiving a lipid-lowering agent | 8.90% | x | x | x | x | x | x | Data extracted on investigating hypertensive patients based on LDL-C, HDL, and TG levels | |